Stockscreener 앱 받기
129.11
1.39%
1.77
시간 외 거래:
134.00
4.89
+3.79%
전일 마감가:
$127.34
열려 있는:
$127.34
하루 거래량:
2.10M
Relative Volume:
0.96
시가총액:
$17.12B
수익:
$1.08B
순이익/손실:
$-433.19M
주가수익비율:
-37.97
EPS:
-3.4004
순현금흐름:
$-225.09M
1주 성능:
-1.22%
1개월 성능:
+36.02%
6개월 성능:
+32.46%
1년 성능:
+160.67%
1일 변동 폭
$125.00
$130.79
1주일 범위
$125.00
$135.00
52주 변동 폭
$40.35
$135.00
가든트헬스 Stock (GH) Company Profile
명칭
Guardant Health Inc
전화
855-698-8887
주소
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
129.11 | 17.21B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
461.69 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.76 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
546.09 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
124.33 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
357.00 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
가든트헬스 Stock (GH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 재확인 | Canaccord Genuity | Buy |
| 2026-02-17 | 개시 | Robert W. Baird | Outperform |
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-09-25 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | 재개 | Wells Fargo | Overweight |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-28 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-24 | 재개 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-09-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-11-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | 개시 | Craig Hallum | Buy |
| 2022-10-06 | 개시 | Stephens | Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-04-28 | 재개 | BTIG Research | Buy |
| 2022-02-24 | 재확인 | Canaccord Genuity | Buy |
| 2022-02-24 | 재확인 | Citigroup | Buy |
| 2022-02-24 | 재확인 | Cowen | Outperform |
| 2022-02-24 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-24 | 재확인 | SVB Leerink | Outperform |
| 2022-02-24 | 재확인 | Stifel | Buy |
| 2022-02-24 | 재확인 | Wells Fargo | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-11 | 개시 | Stifel | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-06-12 | 개시 | BTIG Research | Buy |
| 2020-02-21 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-08-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-04-16 | 개시 | Canaccord Genuity | Buy |
| 2019-04-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | 재확인 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | JP Morgan | Overweight |
| 2018-10-29 | 개시 | William Blair | Outperform |
모두보기
가든트헬스 주식(GH)의 최신 뉴스
[Form 4] Guardant Health, Inc. Insider Trading Activity - Stock Titan
GH (GH) affiliate Kumud Kalia notifies proposed sale of 5,000 shares - Stock Titan
GH (NASDAQ: GH) amendment: affiliate sold 5,000 shares for $652,030 - Stock Titan
Kumud Kalia sells shares; GH (NASDAQ: GH) Form 144 lists dates and proceeds - Stock Titan
The Technical Signals Behind (GH) That Institutions Follow - Stock Traders Daily
Guardant Health Inc. (NASDAQ:GH) Shines as a Top Minervini Trend Template and High Growth Momentum Pick - ChartMill
What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook - Kavout
Guardant rated new outperform at RBC on catalysts, growth prospects - MSN
Top Guardant Health Executive Makes Major Insider Move - TipRanks
Guardant Health CIO Kalia sells $652,030 in company stock By Investing.com - Investing.com Australia
Guardant Health CIO Kalia sells $652,030 in company stock - Investing.com
Insider Sell: Kumud Kalia Sells 5,000 Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health Chief Information Officer Sold Shares Worth Over $652K - TradingView
Guardant Health (GH) CIO Kumud Kalia sells 5,000 shares in open market - Stock Titan
Guardant Health (GH) Receives Outperform Rating from RBC Capital Markets - GuruFocus
Guardant Health rated new Outperform at RBC (GH:NASDAQ) - Seeking Alpha
Guardant Health Set to Benefit From Genomic Profiling Growth, RBC Says - Moomoo
RBC Capital Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $185 - Moomoo
RBC Capital Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $185 - Moomoo
RBC Capital initiates Guardant Health stock coverage with outperform rating - Investing.com
RBC Capital initiates Guardant Health stock coverage with outperform rating By Investing.com - Investing.com Canada
GH Receives FDA Approval for Guardant360 CDx as Companion Diagno - GuruFocus
Guardant Health wins FDA approval for HER2 lung cancer test By Investing.com - Investing.com Australia
Guardant Health wins FDA approval for HER2 lung cancer test - Investing.com
Guardant Health, Inc. Announces FDA Approval Of Guardant360 CDx As Companion Diagnostic For Boehringer Ingelheim?s HERNEXEOS - marketscreener.com
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS - The Joplin Globe
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health co-CEO Helmy Eltoukhy sells $12.6m in stock By Investing.com - Investing.com South Africa
Guardant Health Insider Sold Shares Worth $12,629,969, According to a Recent SEC Filing - Moomoo
Insider Sell: Michael Bell Sells 2,000 Shares of Guardant Health Inc (GH) - GuruFocus
GH Maintained by Mizuho -- Price Target Raised to $175 - GuruFocus
Guardant Health CFO Michael Bell sells $257,240 in company shares By Investing.com - Investing.com Nigeria
Guardant Health co-CEO Helmy Eltoukhy sells $12.6m in stock - Investing.com India
Guardant Health CFO Michael Bell sells $257,240 in company shares - Investing.com
Guardant Health (NASDAQ: GH) co-CEO’s trust sells 100,000 shares in open market - Stock Titan
Guardant Health (GH) CFO sells 2,000 shares in open-market trade - Stock Titan
HHS indicates skepticism on international cancer risk assessments - Seeking Alpha
Mizuho raises Guardant Health stock price target to $175 on FDA approval By Investing.com - Investing.com South Africa
Mizuho raises Guardant Health stock price target to $175 on FDA approval - Investing.com Canada
Why Grail Could Be the Sleeper Stock Everyone's About to Notice - The Motley Fool
Guardant Health, Inc. (GH) Stock Analysis: Navigating a 9.14% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Goldman Sachs Initiates Guardant Health(GH.US) With Buy Rating, Announces Target Price $165 - Moomoo
Insider Sale: Director at $GH Sells 9,294 Shares - Moomoo
Insider Sell: Steve Krognes Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health director Steve Krognes sells $1.23m in stock By Investing.com - Investing.com South Africa
Guardant Health director Steve Krognes sells $1.23m in stock - Investing.com
Guardant Health (NASDAQ: GH) director sells 9,294 shares in open-market trade - Stock Titan
Guardant Health, Inc. (GH) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
GH Initiates Coverage On Goldman Sachs -- Rating Set to Buy - GuruFocus
GH (Nasdaq) Form 144: Brokered RSU sale schedule via Stifel Nicolaus - Stock Titan
Guardant Health (NASDAQ: GH) Form 144: 2,000 shares listed, 3,000 sold - Stock Titan
가든트헬스 (GH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
가든트헬스 주식 (GH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tariq Musa | Director |
Jun 16 '26 |
Sale |
130.19 |
116 |
15,102 |
8,796 |
| Saia John G. | Chief Legal Officer |
Jun 15 '26 |
Option Exercise |
0.00 |
1,020 |
0 |
36,970 |
| Freeman Chris | Chief Commercial Officer |
Jun 15 '26 |
Option Exercise |
0.00 |
1,402 |
0 |
61,695 |
| Bell Michael Brian | Chief Financial Officer |
Jun 15 '26 |
Option Exercise |
0.00 |
2,039 |
0 |
49,548 |
1.63%
2.88%
자본화:
|
볼륨(24시간):